12:00 PM Panel Discussion: Defining Surrogate Endpoints for Rare & Genetic Kidney Disease
Time: 12:00 pm
day: Conference Day 1
Details:
- Current regulatory perspectives on surrogate endpoints such as proteinuria in rare kidney diseases
- Industry perspectives on balancing the need for a 'registrable' surrogate endpoint with the goal of achieving a 'clinically compelling' outcome for patients
- Patient views on the use of surrogate endpoints in clinical trials
